Bulk Pharmaceutical API Sources for POLYCILLIN-N

Bulk Pharmaceutical API Sources for POLYCILLIN-N

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		A9393_SIGMA
NovoSeek		6249
TCI (Tokyo Chemical Industry)		A2092
MolPort		MolPort-001-794-635

Bulk Active Pharmaceutical Ingredient (API) Sources for Polycillin-N

Last updated: February 19, 2026

This report identifies and analyzes key suppliers of bulk Amoxicillin Trihydrate, the active pharmaceutical ingredient (API) in Polycillin-N, focusing on manufacturing capacity, regulatory compliance, and market presence. The analysis targets business professionals involved in pharmaceutical supply chain management, R&D, and investment.

What is Polycillin-N?

Polycillin-N is a brand name for amoxicillin, a penicillin-class antibiotic used to treat a variety of bacterial infections. It functions by inhibiting bacterial cell wall synthesis, a mechanism crucial for its antimicrobial efficacy. The active pharmaceutical ingredient (API) is Amoxicillin Trihydrate.

Global Amoxicillin Trihydrate API Market Overview

The global market for Amoxicillin Trihydrate API is characterized by a significant number of manufacturers, primarily located in Asia, with China and India dominating production volume. The market is competitive, with pricing influenced by raw material costs, manufacturing efficiency, and regulatory hurdles. Demand is driven by the widespread use of amoxicillin for common infections, its affordability, and its inclusion in essential medicine lists by the World Health Organization.

Key Manufacturers of Amoxicillin Trihydrate API

The following entities are identified as significant manufacturers and suppliers of bulk Amoxicillin Trihydrate API, based on publicly available information regarding their production capabilities, regulatory filings, and market reach.

Chinese Manufacturers

China is a leading global producer of Amoxicillin Trihydrate API. Key players include:

• Qilu Pharmaceutical Co., Ltd.: A major pharmaceutical enterprise with extensive API manufacturing capabilities. Qilu is known for its broad portfolio of antibiotics.
• Zhejiang NHU Co., Ltd.: A significant player in the fine chemical and API sector, including antibiotics. NHU operates multiple production facilities and adheres to international quality standards.
• CSPC Pharmaceutical Group Limited: A diversified pharmaceutical company with substantial API production. They maintain a strong focus on antibiotic manufacturing.
• Anhui BBCA Pharmaceutical Co., Ltd.: Engaged in the production of various APIs, including amoxicillin. Their operations are typically geared towards large-scale output.
• Shanxi Ciyuan Biotechnology Co., Ltd.: Another contributor to China's API export market for antibiotics.

Indian Manufacturers

India also holds a substantial share in the global Amoxicillin Trihydrate API market. Prominent manufacturers include:

• Sun Pharmaceutical Industries Ltd.: One of the largest pharmaceutical companies in India, with robust API manufacturing operations and a global distribution network.
• Dr. Reddy's Laboratories Ltd.: A well-established pharmaceutical company with significant API production capacity, including antibiotics.
• Divi's Laboratories Limited: While often known for other APIs, Divi's has capabilities that can extend to antibiotic intermediates and APIs.
• Laurus Labs Limited: Increasingly recognized for its API manufacturing expertise, including a growing portfolio of therapeutic areas.
• Aurobindo Pharma Limited: A major pharmaceutical player with strong vertical integration, including API production for its finished dosage forms and external sales.

Other International Manufacturers

While China and India are dominant, other regions contribute to the supply:

• Sanofi S.A. (France/Global): As a major pharmaceutical originator, Sanofi has historically been involved in amoxicillin production, though much of its bulk API sourcing may be outsourced or consolidated.
• Pfizer Inc. (USA/Global): Similar to Sanofi, Pfizer has a historical presence in amoxicillin and likely utilizes strategic API sourcing.

Regulatory Compliance and Quality Standards

Suppliers of Amoxicillin Trihydrate API for the Polycillin-N market must adhere to stringent regulatory requirements. Key certifications and compliance measures include:

• US Food and Drug Administration (FDA) Approval: Inclusion on the FDA's drug master file (DMF) list and successful FDA inspections are critical for market access in the United States.
• European Directorate for the Quality of Medicines & HealthCare (EDQM) Certification: Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are essential for the European market.
• World Health Organization (WHO) Good Manufacturing Practices (GMP): Compliance with WHO GMP standards is a prerequisite for supply to many international markets and organizations.
• Other National Regulatory Agencies: Approvals from agencies in Japan (PMDA), Canada (Health Canada), and other major pharmaceutical markets are important.

Manufacturers typically provide Certificates of Analysis (CoA) with each batch, detailing critical quality attributes such as:

• Assay: Minimum 95.0% to 100.0% of amoxicillin.
• Water Content: Typically not more than 12.5%.
• Specific Rotation: Within specified ranges to confirm enantiomeric purity.
• Identification Tests: Using Infrared Spectroscopy (IR) and High-Performance Liquid Chromatography (HPLC).
• Related Substances/Impurities: Strict limits on known and unknown impurities.
• Residual Solvents: Compliance with ICH guidelines.
• Particle Size Distribution: Can be a critical parameter for downstream processing.

Manufacturing Processes and Capacity

The synthesis of Amoxicillin Trihydrate typically involves a multi-step process starting from 6-aminopenicillanic acid (6-APA) and D-(-)-4-hydroxyphenylglycine derivatives. Production capacity is a significant factor in supplier reliability and pricing. Manufacturers with large-scale fermentation and synthesis capabilities can achieve economies of scale.

Capacity Indicators

While precise, real-time capacity figures are proprietary, industry estimates and filings provide a general indication:

• Major Chinese Manufacturers: Often possess capacities in the thousands of metric tons per annum for key antibiotic APIs like Amoxicillin.
• Major Indian Manufacturers: Similarly operate at large scales, with individual company capacities potentially exceeding 1,000-2,000 metric tons annually.

Capacity can fluctuate based on market demand, raw material availability, and regulatory updates that might require process modifications or revalidation.

Sourcing Considerations for Polycillin-N Manufacturers

When selecting a bulk Amoxicillin Trihydrate API supplier, manufacturers of Polycillin-N should consider the following:

• Regulatory Approvals: Prioritize suppliers with DMFs filed and accepted by target markets (FDA, EDQM).
• Quality Management Systems: Ensure robust QMS, evident through ISO certifications and a history of successful regulatory inspections.
• Supply Chain Reliability: Assess supplier's historical performance regarding on-time delivery and consistency of quality.
• Geopolitical and Economic Stability: Diversify sourcing to mitigate risks associated with single-country dependence.
• Cost-Effectiveness: While quality and reliability are paramount, competitive pricing is a significant factor in a high-volume API market.
• Technical Support: The supplier's ability to provide technical assistance, troubleshoot formulation issues, and support regulatory filings.
• Auditing: Conduct thorough on-site audits of potential suppliers' manufacturing facilities to verify compliance and operational standards.

Market Trends and Future Outlook

The market for Amoxicillin Trihydrate API is expected to remain stable, driven by its established position in treating bacterial infections. Key trends influencing the market include:

• Increasing Focus on API Purity and Impurity Profiling: Regulatory bodies are placing greater emphasis on identifying and controlling impurities, requiring suppliers to invest in advanced analytical capabilities.
• Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities in global supply chains, prompting many pharmaceutical companies to seek diversified and resilient sourcing strategies.
• Cost Pressures: While demand is steady, significant price competition persists among API manufacturers, especially in the generic sector.
• Environmental Regulations: Stricter environmental regulations in manufacturing hubs like China are impacting production costs and potentially influencing supply dynamics.

Key Takeaways

• Amoxicillin Trihydrate, the API for Polycillin-N, is predominantly manufactured in China and India.
• Key Chinese suppliers include Qilu Pharmaceutical, Zhejiang NHU, and CSPC Pharmaceutical Group.
• Major Indian suppliers are Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Aurobindo Pharma.
• Regulatory compliance (FDA, EDQM, WHO GMP) is a critical differentiator and a prerequisite for market access.
• Buyers should assess suppliers on quality, reliability, regulatory standing, and cost-effectiveness.
• Supply chain diversification and robust quality management systems are essential for mitigating risks.

Frequently Asked Questions

1. What are the primary regulatory requirements for Amoxicillin Trihydrate API suppliers? Suppliers must meet Good Manufacturing Practices (GMP) standards, often verified through audits by regulatory agencies such as the US FDA and the European Directorate for the Quality of Medicines & HealthCare (EDQM). Filing and acceptance of Drug Master Files (DMFs) in target markets are also critical.

2. How can a pharmaceutical company assess the manufacturing capacity and reliability of an API supplier? Assessment involves reviewing the supplier's historical delivery performance, conducting site audits to observe production scale and process controls, verifying their quality management systems, and discussing their contingency plans for supply disruptions.

3. What are the main quality parameters to monitor for Amoxicillin Trihydrate API? Key quality parameters include assay, water content, specific rotation, identification tests (e.g., IR, HPLC), limits for related substances and impurities, residual solvents, and particle size distribution, all specified by pharmacopoeial monographs (e.g., USP, EP).

4. Beyond cost, what are the most important factors when selecting a bulk API supplier? Beyond cost, critical factors include robust regulatory compliance and a history of successful inspections, consistent product quality, supply chain transparency and reliability, strong technical support, and adherence to ethical and environmental standards.

5. How does geopolitical instability in API manufacturing regions affect the sourcing of Amoxicillin Trihydrate? Geopolitical instability can lead to supply chain disruptions, increased lead times, and price volatility. It underscores the need for pharmaceutical companies to diversify their supplier base across different geographic regions and to implement robust risk management strategies.

---

Cited Sources

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA Website] (Specific URL may vary, general access to DMF information is available on FDA.gov) [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability. Retrieved from [EDQM Website] (Specific URL may vary, general information on CEPs is available on edqm.eu) [3] World Health Organization. (n.d.). Good Manufacturing Practices for Pharmaceutical Products. Retrieved from [WHO Website] (Specific URL may vary, GMP guidelines are available on who.int) [4] United States Pharmacopeia. (n.d.). Amoxicillin Trihydrate Monograph. Retrieved from [USP Website] (Access typically requires subscription to pharmacopoeias) [5] European Pharmacopoeia. (n.d.). Amoxicillin Trihydrate Monograph. Retrieved from [EDQM Website] (Access typically requires subscription to pharmacopoeias) [6] Publicly available company reports and investor relations materials from Qilu Pharmaceutical, Zhejiang NHU Co., Ltd., CSPC Pharmaceutical Group Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited. (Specific reports and URLs vary by company and reporting period.)